Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...
Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset——Joint poster presentation with Bachem to ...
SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies in ...
Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease ...
AstraZeneca and TotalEnergies are among the stocks that fell into undervalued territory. We sell different types of products and services to both investment professionals and individual investors ...
The poster to be presented at ASH 2024 will provide a clinical update of the ongoing first-in-human dose-escalation phase 1/2a study of MP0533 in patients with relapsed/refractory acute myeloid ...
Poster presentations across all programs, including updates from ongoing clinical studies and new translational data in ...
allowing for control of tumors in vivo without the need for exogenous or engineered cytokines- - Posters include demonstration of advances in gene editing and transgene design that enable greater ...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...
Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMTâ„¢ plus immune check point inhibitor in metastatic breast cancer Presentations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback